--- title: "Charles River Laboratorie | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 994.23 M" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276225987.md" datetime: "2026-02-18T12:15:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276225987.md) - [en](https://longbridge.com/en/news/276225987.md) - [zh-HK](https://longbridge.com/zh-HK/news/276225987.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/276225987.md) | [English](https://longbridge.com/en/news/276225987.md) # Charles River Laboratorie | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 994.23 M Revenue: As of FY2025 Q4, the actual value is USD 994.23 M, beating the estimate of USD 986.98 M. EPS: As of FY2025 Q4, the actual value is USD -5.62, missing the estimate of USD 1.3533. EBIT: As of FY2025 Q4, the actual value is USD -260.68 M. ### Fourth-Quarter 2025 Financial Performance #### Consolidated Results - **Total Revenue**: Charles River Laboratories International, Inc. reported $994.2 million in revenue for the fourth quarter of 2025, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. Foreign currency translation positively impacted reported revenue by 1.9%, while a divestiture reduced it by 0.1%. On an organic basis, revenue declined 2.6%, primarily due to the Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing) segments . - **GAAP Operating Margin**: The GAAP operating margin was -28.5%, compared to -16.7% in the fourth quarter of 2024 . - **GAAP Net Loss**: The GAAP net loss available to common shareholders was - $276.6 million, or - $5.62 per diluted share, for the fourth quarter of 2025, compared to a net loss of - $215.7 million, or - $4.22 per diluted share, for the same period in 2024. This included non-cash intangible asset impairments of $211.0 million (or $3.22 per share) and a non-cash goodwill impairment of $165.0 million (or $3.35 per share) in the fourth quarter of 2025 . - **Non-GAAP Operating Margin**: The non-GAAP operating margin decreased to 18.1% from 19.9% in the fourth quarter of 2024 . - **Non-GAAP Net Income**: Non-GAAP net income was $118.8 million, a decrease of 13.0% from $136.6 million in the fourth quarter of 2024 . #### Segment Performance (Fourth Quarter 2025) - **Research Models and Services (RMS)**: - Revenue: $206.3 million, an increase of 1.0% from $204.3 million in the fourth quarter of 2024. Organic revenue decreased by 0.9% . - GAAP Operating Margin: -33.6%, down from 6.7% in the fourth quarter of 2024 due to an intangible asset impairment . - Non-GAAP Operating Margin: Decreased to 21.9% from 22.8% . - **Discovery and Safety Assessment (DSA)**: - Revenue: $591.6 million, a decrease of 2.0% from $603.3 million in the fourth quarter of 2024. Organic revenue decreased by 3.3% . - GAAP Operating Margin: Increased to 14.3% from 10.4% in the fourth quarter of 2024 . - Non-GAAP Operating Margin: Decreased to 20.1% from 24.7% in the fourth quarter of 2024 . - **Manufacturing Solutions (Manufacturing)**: - Revenue: $196.4 million, an increase of 0.7% from $194.9 million in the fourth quarter of 2024. Organic revenue decreased 2.1% . - GAAP Operating Margin: -115.9%, compared to -93.6% in the fourth quarter of 2024 due to larger impairments . - Non-GAAP Operating Margin: Increased to 32.1% from 28.7% in the fourth quarter of 2024 . ### Full-Year 2025 Financial Performance #### Consolidated Results - **Total Revenue**: Charles River Laboratories International, Inc. reported $4.02 billion for the full year 2025, a decrease of 0.9% from $4.05 billion in 2024. Organic revenue declined by 1.6% . - **GAAP Operating Margin**: Decreased to 0.6% from 5.6% in 2024 . - **Non-GAAP Operating Margin**: Decreased to 19.8% from 19.9% in 2024 . - **GAAP Net Loss**: - $144.3 million, compared to net income of $10.3 million in 2024 . - **Non-GAAP Net Income**: $512.3 million, a decrease of 3.9% from $532.9 million in 2024 . #### Cash Flow (Full-Year 2025) - **Net Cash Provided by Operating Activities**: $737.6 million, compared to $734.6 million in 2024 . - **Capital Expenditures**: - $219.2 million, compared to - $233.0 million in 2024 . ### 2026 Guidance 查尔斯河 (Charles River Laboratories International, Inc.) anticipates 2026 reported revenue growth to be at least flat to +1.5%, with organic revenue growth expected to be -1.0% to at least flat . Non-GAAP earnings per share are projected to increase by approximately 4% to 9%, reaching an estimated range of $10.70 to $11.20 . This outlook assumes a return to organic revenue growth in the second half of 2026 for both consolidated results and the DSA segment, along with increased revenue in the Manufacturing segment . ### 相關股票 - [Charles River Laboratorie (CRL.US)](https://longbridge.com/zh-HK/quote/CRL.US.md) ## 相關資訊與研究 - [Charles River Laboratories International Inc. Stock Underperforms Wednesday When Compared To Competitors](https://longbridge.com/zh-HK/news/272609495.md) - [Charles River Laboratories International Inc. Stock Underperforms Wednesday When Compared To Competitors](https://longbridge.com/zh-HK/news/265597210.md) - [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/zh-HK/news/281225115.md) - [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/zh-HK/news/281530653.md) - [Inky Updates Bylaws Following Recent Fiscal Year Change](https://longbridge.com/zh-HK/news/281297268.md)